Allergan May Add New Non-Cosmetic Use to Botox

Allergan’s supplemental biologics license application (sBLA) for a Botox label expansion to idiopathic overactive bladder (OAB) may receive a final decision this month.

The application has a PDUFA date in January, according to estimates by Bloomberg Industries, which are based on the company’s submission in both the U.S.

Click here to continue reading.

Bloomberg BRIEF Newsletters

Insight.
Delivered.

Newsletters For Professionals,
From Professionals.



Select Brief to Subscribe
or for a free trial.





Back_issues